Catalent Pharma Solutions
NDC Database
Catalent Pharma Solutions
NDC Database
National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.
- Total Records 269
- Latest Marketing Date 2026-04-16
- Data Source FDA
- First Marketing Date 1958-02-10
Company Overview
Social Profiles
Company Snapshot
Catalent Pharma Solutions
14 Schoolhouse Road, Somerset, NJ 08873
U.S.A
www.catalent.com/ marketing@catalent.com View on MapNDC Records ( 269 records )
Nonproprietary Name
Naproxen Sodium
Dosage Form
CAPSULE
Strength
220 mg/1
Labeler
Catalent Argentina S.A.I.y C.
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NAPROXEN SODIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-02-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Isotretinoin
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent France Beinheim S.A
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ISOTRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2002-11-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Isotretinoin
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Catalent France Beinheim S.A.
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ISOTRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2002-11-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tretinoin
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent France Beinheim SA
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
isotretinoin
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent France Beinheim SA
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ISOTRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2002-11-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Isotretinoin
Dosage Form
CAPSULE
Strength
30 mg/1
Labeler
Catalent France Beinheim SA
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ISOTRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-09-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Calcitriol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
0.25 ug/1
Labeler
Catalent Germany Eberbach GmBH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CALCITRIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2001-10-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Etoposide
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Catalent Germany Eberbach GmBH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ETOPOSIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2001-11-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Calcitriol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
0.5 ug/1
Labeler
Catalent Germany Eberbach GmBH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CALCITRIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2001-10-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
METYRAPONE
Dosage Form
CAPSULE
Strength
250 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METYRAPONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-08-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Midostaurin
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MIDOSTAURIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nintedanib
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Germany Eberbach GmBH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NINTEDANIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-10-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nintedanib
Dosage Form
CAPSULE
Strength
150 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NINTEDANIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-10-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
TRETINOIN
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-10-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tretinoin
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TRETINOIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-07
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Talazoparib tosylate
Dosage Form
CAPSULE
Strength
0.1 min/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TALAZOPARIB TOSYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Talazoparib tosylate
Dosage Form
CAPSULE
Strength
0.25 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TALAZOPARIB TOSYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Talazoparib tosylate
Dosage Form
CAPSULE
Strength
0.35 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TALAZOPARIB TOSYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Talazoparib tosylate
Dosage Form
CAPSULE
Strength
0.75 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TALAZOPARIB TOSYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Talazoparib tosylate
Dosage Form
CAPSULE
Strength
1 mg/1
Labeler
Catalent Germany Eberbach GmbH
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TALAZOPARIB TOSYLATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-04-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
enzalutamide
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENZALUTAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-08-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
400 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-06-13
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-03-16
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
lubiprostone
Dosage Form
CAPSULE, GELATIN COATED
Strength
8 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LUBIPROSTONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-01-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
lubiprostone
Dosage Form
CAPSULE, GELATIN COATED
Strength
24 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LUBIPROSTONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-01-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Calcitriol
Dosage Form
CAPSULE, GELATIN COATED
Strength
0.5 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CALCITRIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Calcitriol
Dosage Form
CAPSULE, GELATIN COATED
Strength
0.25 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CALCITRIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
bexarotene
Dosage Form
CAPSULE, LIQUID FILLED
Strength
75 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BEXAROTENE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1999-12-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ibuprofen, pseudoephedrine HCl
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200; 30 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2002-05-30
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1995-04-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
diphenhydramine HCl, ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25; 200 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-12-20
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
diphenhydramine hydrochloride
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-03-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Dihpenhydramine Hydrochloride
Dosage Form
CAPSULE, LIQUID FILLED
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-10-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Calcitriol
Dosage Form
CAPSULE
Strength
0.25 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CALCITRIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2006-03-27
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Dextromethorphan hydrobromide and Guaifenesin
Dosage Form
CAPSULE, GELATIN COATED
Strength
10; 200 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-08-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Diphenhydramine HCl
Dosage Form
CAPSULE, LIQUID FILLED
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ergocalciferol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
1.25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ERGOCALCIFEROL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1974-11-11
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
dutasteride
Dosage Form
CAPSULE, GELATIN COATED
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2002-12-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
doxercalciferol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
0.5 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DOXERCALCIFEROL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
DOXERCALCIFEROL
Dosage Form
CAPSULE, LIQUID FILLED
Strength
1 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DOXERCALCIFEROL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-08-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Loratadine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LORATADINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2008-06-16
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
cyclosporine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1995-07-14
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
cyclosporine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1995-07-14
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Nifedipine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIFEDIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1991-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nifedipine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIFEDIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1990-09-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
NIFEDIPINE
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIFEDIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1981-12-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Progesterone
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-07-30
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
cyclosporine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1990-03-02
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
cyclosporine
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1990-03-02
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Progesterone
Dosage Form
CAPSULE, GELATIN COATED
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Progesterone
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2012-03-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
benzonatate
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BENZONATATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1958-02-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Miconazole Nitrate
Dosage Form
INSERT
Strength
1200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MICONAZOLE NITRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-06-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
tipranavir
Dosage Form
CAPSULE, LIQUID FILLED
Strength
250 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TIPRANAVIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2005-07-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ethosuximide
Dosage Form
CAPSULE
Strength
250 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ETHOSUXIMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-09-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Valproic Acid
Dosage Form
CAPSULE, LIQUID FILLED
Strength
250 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VALPROIC ACID
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-09-08
End Marketing Date
2027-12-31
Listing Record Certified Through
-
Nonproprietary Name
Progesterone
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-07-30
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ergocalciferol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
1.25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ERGOCALCIFEROL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1974-11-11
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Valproic Acid
Dosage Form
CAPSULE, LIQUID FILLED
Strength
250 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VALPROIC ACID
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1991-10-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
diphenhydramine hydrochloride
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-03-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Miconazole Nitrate
Dosage Form
INSERT
Strength
1200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MICONAZOLE NITRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2001-06-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Methylphenidate Hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METHYLPHENIDATE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2012-01-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Methylphenidate Hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
30 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METHYLPHENIDATE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2012-01-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Doxycycline
Dosage Form
CAPSULE, DELAYED RELEASE
Strength
40 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DOXYCYCLINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2010-05-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
BEAD
Strength
1 kg/kg
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-07-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
clobazam
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOBAZAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2011-10-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
clobazam
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLOBAZAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2013-08-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
tolterodine tartrate
Dosage Form
CAPSULE
Strength
4 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOLTERODINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-12-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
tolterodine tartrate
Dosage Form
CAPSULE
Strength
2 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOLTERODINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2000-12-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
clindamycin palmitate hydrochloride
Dosage Form
GRANULE, FOR SOLUTION
Strength
75 mg/kg
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CLINDAMYCIN PALMITATE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1986-04-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Colestipol Hydrochloride
Dosage Form
TABLET
Strength
1 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
COLESTIPOL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1994-07-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Colestipol Hydrochloride
Dosage Form
CAPSULE
Strength
1 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
COLESTIPOL HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1994-07-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Tecovirimat
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TECOVIRIMAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-21
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-08-16
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-04-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-07-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-07-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
150 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-07-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-07-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
18.66; 92 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2012-09-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
14; 69 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2012-09-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
9.33; 46 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2012-09-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
4.67; 23 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2012-09-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ibrutinib
Dosage Form
CAPSULE
Strength
140 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-11-07
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Atazanavir
Dosage Form
POWDER
Strength
50 mg/kg
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ATAZANAVIR SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-12-19
End Marketing Date
2027-09-30
Listing Record Certified Through
-
Nonproprietary Name
Progesterone
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-04-28
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Dextromethophan HBR, Pseudoephedrine, Acetaminophen, Guaifenesin
Dosage Form
CAPSULE
Strength
250; 10; 100; 30 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PSEUDOEPHEDRINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-05-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Simethicone
Dosage Form
CAPSULE
Strength
125 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIMETHICONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-12-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Palonosetron Hydrochloride
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PALONOSETRON HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-10-09
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ferrous Fumarate
Dosage Form
CAPSULE
Strength
75 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
FERROUS FUMARATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-02-13
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Calcifediol
Dosage Form
CAPSULE
Strength
30 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CALCIFEDIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-09-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Tafamidis Meglumine
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TAFAMIDIS MEGLUMINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-05-05
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Pirfenidone
Dosage Form
CAPSULE
Strength
267 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PIRFENIDONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-10-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Dutasteride
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-12-19
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Dutasteride
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-04-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Rhinadvil Cold and Sinus
Dosage Form
CAPSULE
Strength
200; 30 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-03-15
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Dutateride Alopecia 0.1mg
Dosage Form
CAPSULE
Strength
0.1 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-02-24
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Advil RF
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-03-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Methylphenidate Hydrochloride
Dosage Form
CAPSULE
Strength
60 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DEXMETHYLPHENIDATE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2017-08-15
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amantadine
Dosage Form
CAPSULE
Strength
68.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMANTADINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-01-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
secnidazole
Dosage Form
POWDER
Strength
2 g/4.8g
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SECNIDAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-10-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Amantadine
Dosage Form
CAPSULE
Strength
137 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMANTADINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-08-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Dutasteride
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-11-20
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Lofexidine
Dosage Form
TABLET, FILM COATED
Strength
0.18 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LOFEXIDINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-05-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Methylphenidate Hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METHYLPHENIDATE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2018-02-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Dextroamphetamine Sulfate
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
1976-08-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Dextroamphetamine Sulfate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
15 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
1976-08-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibrutinib
Dosage Form
TABLET, FILM COATED
Strength
140 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibrutinib
Dosage Form
TABLET, FILM COATED
Strength
280 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibrutinib
Dosage Form
TABLET, FILM COATED
Strength
420 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ibrutinib
Dosage Form
TABLET, FILM COATED
Strength
560 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Apalutamide
Dosage Form
TABLET, FILM COATED
Strength
60 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
APALUTAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-05-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Paricalcitol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
2 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PARICALCITOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-04-08
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Paricalcitol
Dosage Form
CAPSULE, LIQUID FILLED
Strength
1 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PARICALCITOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-04-06
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Estradiol and Progesterone
Dosage Form
CAPSULE
Strength
.5; 100 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESTRADIOL; PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-01-31
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Dutasteride
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-04-18
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Nifedipine
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIFEDIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-01-21
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Nifedipine
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIFEDIPINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-01-27
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Miconazole Nitrate
Dosage Form
SUPPOSITORY
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MICONAZOLE NITRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2009-12-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Encorafenib
Dosage Form
CAPSULE
Strength
75 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENCORAFENIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-30
End Marketing Date
2027-10-31
Listing Record Certified Through
-
Nonproprietary Name
Encorafenib
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENCORAFENIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-30
End Marketing Date
2027-08-30
Listing Record Certified Through
-
Nonproprietary Name
Estradiol and Progesterone
Dosage Form
CAPSULE
Strength
1; 100 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESTRADIOL; PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-01-15
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
duvelisib
Dosage Form
CAPSULE
Strength
15 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUVELISIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
duvelisib
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DUVELISIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Acetaminophen
Dosage Form
CAPSULE
Strength
325 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ACETAMINOPHEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2015-02-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Estradiol and Norethindrone Acetate
Dosage Form
CAPSULE
Strength
20; 1 ug/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-07-12
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-11-25
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-03-10
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Miconazole Nitrate
Dosage Form
CAPSULE
Strength
400 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
MICONAZOLE NITRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Methylphenidate Hydrochloride
Dosage Form
CAPSULE
Strength
40 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
METHYLPHENIDATE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2018-12-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE
Strength
1.25; 1.25; 1.25; 1.25 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2019-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE
Strength
2.5; 2.5; 2.5; 2.5 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2019-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE
Strength
3.75; 3.75; 3.75; 3.75 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2019-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE
Strength
5; 5; 5; 5 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2019-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE
Strength
6.25; 6.25; 6.25; 6.25 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2019-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE
Strength
7.5; 7.5; 7.5; 7.5 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2019-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-03-19
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
PELLET
Strength
20 mg/kg
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2007-03-19
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Testosterone Undecanoate
Dosage Form
CAPSULE
Strength
158 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TESTOSTERONE UNDECANOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2014-08-18
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Testosterone Undecanoate
Dosage Form
CAPSULE
Strength
198 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TESTOSTERONE UNDECANOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2017-09-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Testosterone Undecanoate
Dosage Form
CAPSULE
Strength
237 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TESTOSTERONE UNDECANOATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2014-08-25
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Progestrone
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-06-09
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Progestrone
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2004-06-09
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Tafamidis
Dosage Form
CAPSULE
Strength
61 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TAFAMIDIS
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-04-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Dutasteride
Dosage Form
CAPSULE
Strength
0.5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
DUTASTERIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-06-23
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Selinexor
Dosage Form
TABLET, FILM COATED
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SELINEXOR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-07-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
PEXIDARTINIB
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PEXIDARTINIB HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-08-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZANUBRUTINIB
Dosage Form
CAPSULE, GELATIN COATED
Strength
80 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZANUBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-11-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ibrutinib
Dosage Form
TABLET, FILM COATED
Strength
420 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-02-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Diazepam
Dosage Form
SPRAY
Strength
5 mg/100uL
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIAZEPAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2019-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Diazepam
Dosage Form
SPRAY
Strength
7.5 mg/100uL
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIAZEPAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2019-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Diazepam
Dosage Form
SPRAY
Strength
10 mg/100uL
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIAZEPAM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2019-09-05
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Avapritinib
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AVAPRITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-07-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Avapritinib
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AVAPRITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-07-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Avapritinib
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AVAPRITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-07-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Progestrone
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PROGESTERONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-12-06
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
diclofenac
Dosage Form
CAPSULE
Strength
35 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DICLOFENAC
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-02-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibrutinib
Dosage Form
CAPSULE
Strength
70 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2017-12-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Pimavanserin tartrate
Dosage Form
CAPSULE
Strength
34 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PIMAVANSERIN TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-06-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Opicapone
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OPICAPONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-04-24
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Ibuprofen/Diphenhydramine HCl
Dosage Form
CAPSULE
Strength
25; 200 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
DIPHENHYDRAMINE; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2013-04-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ibuprofen
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2014-03-19
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Icosapent Ethyl
Dosage Form
CAPSULE
Strength
1000 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ICOSAPENT ETHYL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
bexarotene
Dosage Form
CAPSULE, LIQUID FILLED
Strength
75 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
BEXAROTENE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
1999-12-29
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Voclosporin
Dosage Form
CAPSULE
Strength
7.9 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VOCLOSPORIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-01-22
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Berotralstat hydrochloride
Dosage Form
CAPSULE
Strength
150 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BEROTRALSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-12-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Calcifediol
Dosage Form
CAPSULE
Strength
30 ug/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
CALCIFEDIOL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2016-09-03
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
levodopa
Dosage Form
CAPSULE
Strength
42 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LEVODOPA
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-08-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Trospium Chloride
Dosage Form
CAPSULE
Strength
60 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
TROSPIUM CHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-03-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
viloxazine hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VILOXAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-04-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
viloxazine hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
150 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VILOXAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-04-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
viloxazine hydrochloride
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VILOXAZINE HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-04-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Voclosporin
Dosage Form
CAPSULE
Strength
7.9 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
VOCLOSPORIN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-18
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ruxolitinib
Dosage Form
TABLET
Strength
5 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RUXOLITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ruxolitinib
Dosage Form
TABLET
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RUXOLITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ruxolitinib
Dosage Form
TABLET
Strength
15 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RUXOLITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ruxolitinib
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RUXOLITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ruxolitinib
Dosage Form
TABLET
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RUXOLITINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2011-11-16
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
telotristat ethyl
Dosage Form
TABLET
Strength
250 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TELOTRISTAT ETHYL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-08-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Voxelotor
Dosage Form
TABLET, FILM COATED
Strength
500 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
VOXELOTOR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-11-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Roxadustat
Dosage Form
TABLET
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
ROXADUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Roxadustat
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
ROXADUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Roxadustat
Dosage Form
TABLET
Strength
70 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
ROXADUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Roxadustat
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
ROXADUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Roxadustat
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
ROXADUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-08-11
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
tucatinib
Dosage Form
TABLET
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TUCATINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-04-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZANUBRUTINIB
Dosage Form
CAPSULE, GELATIN COATED
Strength
80 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
ZANUBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-09-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
tucatinib
Dosage Form
TABLET
Strength
150 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TUCATINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-04-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Icosapent Ethyl
Dosage Form
CAPSULE
Strength
1000 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ICOSAPENT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2021-03-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
PEXIDARTINIB
Dosage Form
CAPSULE
Strength
125 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PEXIDARTINIB HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-10-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
SPARSENTAN
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SPARSENTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
SPARSENTAN
Dosage Form
TABLET, FILM COATED
Strength
400 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SPARSENTAN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-17
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Icosapent Ethyl
Dosage Form
CAPSULE
Strength
500 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ICOSAPENT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-08
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
sodium oxybate
Dosage Form
FOR SUSPENSION, EXTENDED RELEASE
Strength
7.5 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SODIUM OXYBATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2023-10-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
sodium oxybate
Dosage Form
FOR SUSPENSION, EXTENDED RELEASE
Strength
9 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SODIUM OXYBATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2023-10-09
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
enzalutamide
Dosage Form
TABLET
Strength
40 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENZALUTAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
enzalutamide
Dosage Form
TABLET
Strength
80 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENZALUTAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-08-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Zuranolone
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZURANOLONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-08-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZURANOLONE
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZURANOLONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-08-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ZURANOLONE
Dosage Form
CAPSULE
Strength
30 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZURANOLONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2023-08-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Diclofenac
Dosage Form
CAPSULE
Strength
35 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
DICLOFENAC
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-11-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Berotralstat hydrochloride
Dosage Form
CAPSULE
Strength
110 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
BEROTRALSTAT HYDROCHLORIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-10-02
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
daprodustat
Dosage Form
TABLET, FILM COATED
Strength
1 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DAPRODUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
daprodustat
Dosage Form
TABLET, FILM COATED
Strength
2 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DAPRODUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-07-31
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
daprodustat
Dosage Form
TABLET, FILM COATED
Strength
4 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DAPRODUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
daprodustat
Dosage Form
TABLET, FILM COATED
Strength
6 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DAPRODUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Entrectinib
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENTRECTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-10-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Entrectinib
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENTRECTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-10-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ENTRECTINIB
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENTRECTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ENTRECTINIB
Dosage Form
CAPSULE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENTRECTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-10-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
ivacaftor
Dosage Form
GRANULE
Strength
1.92 g/1.92g
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
IVACAFTOR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-10-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
niraparib
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIRAPARIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-10-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Icosapent Ethyl
Dosage Form
CAPSULE
Strength
500 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ICOSAPENT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-03-08
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Niraparib
Dosage Form
TABLET, FILM COATED
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIRAPARIB TOSYLATE MONOHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2022-05-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Niraparib
Dosage Form
TABLET, FILM COATED
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIRAPARIB TOSYLATE MONOHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-08
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Niraparib
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NIRAPARIB TOSYLATE MONOHYDRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-06
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
daprodustat
Dosage Form
TABLET, FILM COATED
Strength
8 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DAPRODUSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-02-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
POSACONAZOLE
Dosage Form
TABLET
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
POSACONAZOLE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2020-11-24
End Marketing Date
2026-07-31
Listing Record Certified Through
-
Nonproprietary Name
ENCORAFENIB
Dosage Form
CAPSULE
Strength
75 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENCORAFENIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-01-17
End Marketing Date
2028-01-31
Listing Record Certified Through
-
Nonproprietary Name
Cyclosporine
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-05-08
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Cysclosporine
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-06-07
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Cyclosporine
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CYCLOSPORINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-05-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
ENCORAFENIB
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENCORAFENIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2018-09-05
End Marketing Date
2027-05-30
Listing Record Certified Through
-
Nonproprietary Name
Crinecerfont
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CRINECERFONT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-09-25
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Crinecerfont
Dosage Form
CAPSULE
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CRINECERFONT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-09-23
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Elacestrant
Dosage Form
TABLET, FILM COATED
Strength
86 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ELACESTRANT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-01-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Elacestrant
Dosage Form
TABLET, FILM COATED
Strength
345 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ELACESTRANT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-01-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lacosamide
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LACOSAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2024-02-25
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lacosamide
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
150 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LACOSAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2024-02-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
lacosamide
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
200 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
LACOSAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CV
Start Marketing Date
2024-02-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
sodium oxybate
Dosage Form
FOR SUSPENSION, EXTENDED RELEASE
Strength
6 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SODIUM OXYBATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2024-01-29
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
orlistat
Dosage Form
CAPSULE
Strength
60 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ORLISTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
opicapone
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OPICAPONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2023-04-26
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Crinecerfont
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
CRINECERFONT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-02-28
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
diphenhydramine HCl, ibuprofen
Dosage Form
CAPSULE, LIQUID FILLED
Strength
25; 200 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-06-17
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-01-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
CAPSULE
Strength
20 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-01-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Esomeprazole Magnesium
Dosage Form
PELLET
Strength
20 mg/kg
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ESOMEPRAZOLE MAGNESIUM
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2019-01-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nilotinib
Dosage Form
TABLET
Strength
71 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NILOTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-12-09
End Marketing Date
2026-09-30
Listing Record Certified Through
-
Nonproprietary Name
Nilotinib
Dosage Form
TABLET
Strength
95 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NILOTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-12-09
End Marketing Date
2026-09-30
Listing Record Certified Through
-
Nonproprietary Name
omega-3-acid ethyl esters
Dosage Form
CAPSULE, LIQUID FILLED
Strength
1 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
OMEGA-3-ACID ETHYL ESTERS
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-02-27
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Relacorilant
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RELACORILANT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-02-11
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
zanubrutinib
Dosage Form
TABLET, FILM COATED
Strength
160 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ZANUBRUTINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-04-12
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
6.25; 6.25; 6.25; 6.25 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2024-04-20
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
9.375; 9.375; 9.375; 9.375 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2024-04-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
12.5; 12.5; 12.5; 12.5 mg/1; mg/1; mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CII
Start Marketing Date
2024-04-23
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
xanomeline and trospium chloride
Dosage Form
CAPSULE
Strength
20; 50 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TROSPIUM CHLORIDE; XANOMELINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-22
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
xanomeline and trospium chloride
Dosage Form
CAPSULE
Strength
20; 100 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TROSPIUM CHLORIDE; XANOMELINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-11-27
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
xanomeline and trospium chloride
Dosage Form
CAPSULE
Strength
30; 125 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
TROSPIUM CHLORIDE; XANOMELINE TARTRATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-12-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Suzetrigine
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUZETRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-02-14
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
selinexor
Dosage Form
TABLET, FILM COATED
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SELINEXOR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-03-10
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Sebetralstat
Dosage Form
TABLET, FILM COATED
Strength
300 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SEBETRALSTAT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-04
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
levodopa
Dosage Form
CAPSULE
Strength
42 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
LEVODOPA
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-09-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Relacorilant
Dosage Form
CAPSULE
Strength
25 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
RELACORILANT
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-08-04
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Pralsetinib
Dosage Form
CAPSULE
Strength
100 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
PRALSETINIB
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-07-30
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nicotine
Dosage Form
LOZENGE
Strength
2 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NICOTINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-02-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nicotine
Dosage Form
LOZENGE
Strength
4 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NICOTINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-02-03
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nicotine
Dosage Form
LOZENGE
Strength
4 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NICOTINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Nicotine
Dosage Form
LOZENGE
Strength
2 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
NICOTINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-01-01
End Marketing Date
-
Listing Record Certified Through
2026-12-31
Nonproprietary Name
Suzetrigine
Dosage Form
TABLET, FILM COATED
Strength
50 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SUZETRIGINE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-08-18
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
18.66; 92 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2024-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
9.33; 46 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2024-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
4.67; 23 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2024-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
phentermine and topiramate
Dosage Form
CAPSULE, EXTENDED RELEASE
Strength
14; 69 mg/1; mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIV
Start Marketing Date
2024-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Apalutamide
Dosage Form
TABLET, FILM COATED
Strength
60 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
APALUTAMIDE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2024-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Ensitrelvir
Dosage Form
TABLET
Strength
125 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ENSITRELVIR
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-04-16
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
sodium oxybate
Dosage Form
FOR SUSPENSION, EXTENDED RELEASE
Strength
4.5 g/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
SODIUM OXYBATE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
CIII
Start Marketing Date
2026-01-01
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Hydrocortisone
Dosage Form
CAPSULE
Strength
10 mg/1
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
EXPORT ONLY
Substance
HYDROCORTISONE
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2025-12-08
End Marketing Date
-
Listing Record Certified Through
2027-12-31
Nonproprietary Name
Etripamil
Dosage Form
SPRAY
Strength
350 mg/mL
Labeler
Catalent Pharma Solutions, LLC
Marketing Category
DRUG FOR FURTHER PROCESSING
Substance
ETRIPAMIL
Product Type
DRUG FOR FURTHER PROCESSING
DEA Schedule
Start Marketing Date
2026-01-05
End Marketing Date
-
Listing Record Certified Through
2027-12-31
NDC Type Breakdown
269 total- Drug for Further Processing
Official Source
NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).
Visit FDA NDC DirectoryNDC Record Details Preview
Explore important National Drug Code information available in the records above.
NDC
49588-0003
Nonproprietary Name
Naproxen Sodium
Labeler
Catalent Argentina S.A.I.y C.
Dosage Form
CAPSULE
FDA NDC Data
National Drug Code information
Regular Updates
Data maintained from official sources
Structured Database
Searchable pharmaceutical data
Reliable Data
Organized NDC records
Create a New Buying Request
Fields marked with * are mandatory.